for over-the-counter medicine and packaged consumer goods during the ongoing coronavirus health crisis.
Johnson & Johnson reported profits of $2.30 per share—higher than the $2 per share forecast by analysts, and sales rose 3.3% from a year ago to $20.7 billion, compared to the $19.5 billion analysts expected.as consumers sought to use over-the-counter medicines to reduce fever and other symptoms associated with coronavirus.by 6.3%, from 95 cents per share to $1.01 per share—a pleasant surprise for investors who have been bracing for the impact of Covid-19 on corporate earnings reports.
The dividend increase came even as the company lowered its full-year forecast for 2020, saying that it expects a decline in sales and higher expenses as it spends more in response to the pandemic.in late March that it plans to begin human trials for the vaccine by September and that it could be widely available by 2021.
skleb1234 They can use that money to pay off the lawsuits.
skleb1234 While initially surprising earnings news, it makes sense given that Johnson & Johnson makes a lot of home goods products and has a large pharmaceutical division. Curious to see how much its stock can rally now in light of the tumble it took a month ago.
skleb1234 They should donate some money and to the heath care system they own everything
skleb1234 Imagine shareholders profiting from death. 😕
skleb1234 Yet no vaccine.
skleb1234 Oh wow 🤦♀️
skleb1234 superb From
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: Forbes - 🏆 394. / 53 続きを読む »
ソース: CNBC - 🏆 12. / 72 続きを読む »
ソース: CNBC - 🏆 12. / 72 続きを読む »